4968.T

• Company Overview & Core Competitiveness

  • Arakawa Chemical is a B2B specialty chemical company founded in 1876 (150th anniversary in 2026), listed on the Tokyo Prime Exchange, with ~1,700 consolidated employees and ~80.0 billion yen 2024 full-year consolidated revenue.
  • The company’s core competitive advantage comes from combining natural rosin (pine resin) processing technology and petrochemical-based material technology, enabling it to serve a wide range of customer needs from everyday consumer products to advanced semiconductor materials. Natural rojin cannot be easily substituted by synthetic products due to its unique mixed composition and compatibility with most materials, with synthetic alternatives requiring tens of times the production cost.
  • The company expanded its business primarily through customer requests from long-standing partnerships with leading industry players, plus proactive development of new strategic areas such as advanced electronic materials.

• Operational Highlights & New Product Progress

  • Three key growth product lines for advanced sectors (photocurative resins, fine chemicals, precision polishing agents for HDDs) recorded strong sales in H1 FY2025. Demand for these products is growing driven by the expansion of generative AI and data center investment, and the company completed all three capacity expansion projects in the past two years to meet future demand.
  • New business progress: 1) Water-based new business: PFAS-free chemicals for paper food containers (to replace PFAS-containing products under regulatory restriction) are currently under customer evaluation. 2) Microalgae business: The company invested in startup SoPros, built a pilot cultivation plant at Osaka factory in July 2025, and currently commercializes microalgae powder in functional consumer products. 3) Pine-derived biotech: Joint research with University of Tsukuba published research showing pine needle extract improves depression symptoms in mouse models, attracting industry attention.
  • Capital and share price awareness: Management recognizes the company’s very low PBR, and will focus on profit harvesting from completed growth market investments, developing new businesses based on biomass materials to improve ROE, PER and PBR. Starting from the next 6th Medium-Term Management Plan, ROIC will be used as a key evaluation metric for capital efficiency.
  • Dividend policy: The company maintains a target 40% payout ratio, kept dividends unchanged during two consecutive years of losses (FY2022 and FY2023), and plans a full-year dividend of 50 yen per share (25 yen interim, 25 yen year-end) for FY2025, targeting a 4%+ dividend yield.

• The company maintains the prior FY2025 full-year guidance with no revision: 85.0 billion yen consolidated revenue (+year-over-year growth), 2.8 billion yen consolidated operating profit (+year-over-year growth), following return to black ink in FY2024 after two consecutive years of losses.
  • The global data center market is expected to grow 1.5x over the next 5 years, and the company expects its fine electronics segment (related to data center and semiconductor supply chains) to reach record full-year sales in FY2025.
  • Growth is expected for Alcon in high-value-added segments (medical patches) in Southeast Asian overseas markets.
  • The 6th Medium-Term Management Plan starting next fiscal year will formally introduce ROIC as a key performance metric, and will detail mid-term targets for segment profitability and growth.

Arakawa Chemical has 4 core operating segments, with no explicit absolute segment revenue figures or full percentage contribution breakdown provided in the transcript. General performance notes: 1. Functional Coating Business: Growing steadily driven by strong demand for its photocurative resins (Beamset, Opstar) used in display and semiconductor-related applications. 2. Paper & Environment Business: Faces intensified price competition in overseas markets; its core product Polystron (paper strength enhancer) is growing in the ASEAN region driven by rising recycled paper demand. 3. Adhesion & Biomass Business: Profit is on a recovery track; the segment’s flagship product Alcon (hydrogenated petroleum resin) is shifting focus from low-margin diaper applications to high-value-added segments such as medical patches and plastic modifiers. 4. Fine Electronics Business: Growing steadily; data center and semiconductor-related products (precision polishing agents Neopolish, fine chemical products) maintained record-high sales, reaching all-time high EBITDA for H1 FY2025. The company is also actively building a fifth new segment: Life Science Business.

• Paper & Environment Business faces intensifying price competition in overseas markets.
  • Fine Electronics Business is exposed to cyclical downturns in the semiconductor and electronic components market, as seen in the 2023 industry downturn that contributed to full-year losses.
  • The Chiba Alcon production site continued to face operational hurdles after startup, though performance is gradually improving.
  • The company has low PBR that management recognizes needs to be improved through better profitability and capital efficiency.
  • Geopolitical risks (such as the Ukraine conflict) can cause sharp spikes in energy and raw material costs.

Q: What caused the two consecutive years of losses in FY2022 and FY2023, and could this happen again? / A: In FY2022, the Ukraine conflict caused natural gas prices to skyrocket at Arakawa Europe’s hydrogenated petroleum resin facility, making the operation unprofitable. Management decided to shut down the plant and record one-time losses. In FY2023, the new Chiba Alcon plant faced startup delays, leading to over 2.0 billion yen in depreciation costs with no revenue, combined with a severe downturn in the global electronics component market. These were mostly one-off combined factors, and operations are now in a recovery trend from FY2024 onward.

Q: What is the company’s approach to product portfolio management and exit/transfer/closure of underperforming businesses? / A: The company follows a regular lifecycle cycle: nurture, grow, harvest, and exit/transfer non-performing businesses. It holds regular business evaluation meetings to set clear milestones for underperforming businesses, and will proceed with exit if targets are not met. For example, the European Alcon business was closed for this reason. Currently there are no businesses planned for exit, but some high-risk businesses will get clearer roadmaps in the next medium-term plan, and some exits are expected in that period.

Q: Why is Arakawa entering the life science business, and what is its strategic potential? / A: The core reason is to diversify away from the cyclical electronics material sector, which is sensitive to economic cycles. Life science is a less cyclical sector that aligns with the company’s core strength of developing products based on natural materials. The company does not aim to be a large B2C player; instead, it targets B2B business development based on functional natural ingredients, to stabilize overall earnings volatility.

Q: What is the outlook for profit margin improvement in the Fine Electronics Business? / A: The segment’s profit margin will improve as sales scale up, though it currently carries high upfront development costs for new products that weigh on margins. This year’s lower year-over-year profit was driven by rising raw material costs with incomplete price pass-through in H1, plus depreciation from the new Mizushima plant pilot line. The company will continue pushing price pass-through in H2, and targets margin expansion as demand grows toward 2030, with formal targets to be released in the next medium-term plan.